Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Blueprint Medicines stock
Learn how to easily invest in Blueprint Medicines stock.
Blueprint Medicines Corp is a biotechnology business based in the US. Blueprint Medicines shares (BPMC) are listed on the NASDAQ and all prices are listed in US Dollars. Blueprint Medicines employs 580 staff and has a trailing 12-month revenue of around $230.5 million.
How to buy shares in Blueprint Medicines
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – BPMC – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Blueprint Medicines stock price (NASDAQ: BPMC)Use our graph to track the performance of BPMC stocks over time.
Blueprint Medicines shares at a glance
|Latest market close||$66.34|
|52-week range||$43.46 - $117.86|
|50-day moving average||$65.90|
|200-day moving average||$68.18|
|Wall St. target price||$90.53|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-11.06|
Buy Blueprint Medicines shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Blueprint Medicines stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Blueprint Medicines price performance over time
|1 week (2022-09-21)||-2.57%|
|1 month (2022-08-26)||-8.15%|
|3 months (2022-06-28)||24.09%|
|6 months (2022-03-28)||1.42%|
|1 year (2021-09-28)||-36.09%|
|2 years (2020-09-28)||-25.36%|
|3 years (2019-09-27)||73.19|
|5 years (2017-09-28)||68.45|
Blueprint Medicines financials
|Revenue TTM||$230.5 million|
|Gross profit TTM||$-446,688,000|
|Return on assets TTM||-31.54%|
|Return on equity TTM||-67.58%|
|Market capitalisation||$3.9 billion|
TTM: trailing 12 months
Blueprint Medicines share dividends
We're not expecting Blueprint Medicines to pay a dividend over the next 12 months.
Blueprint Medicines share price volatility
Over the last 12 months, Blueprint Medicines's shares have ranged in value from as little as $43.46 up to $117.86. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Blueprint Medicines's is 0.7743. This would suggest that Blueprint Medicines's shares are less volatile than average (for this exchange).
Blueprint Medicines overview
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc. ; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc. ; F.
Blueprint Medicines in the news
Blueprint Medicines (BPMC) Rises 68.2% in 3 Months: Here's Why
Why Is Exelixis (EXEL) Down 8.8% Since Last Earnings Report?
Reata Pharmaceuticals, Inc. (RETA) Up 4.7% Since Last Earnings Report: Can It Continue?
Frequently asked questionsWhat percentage of Blueprint Medicines is owned by insiders or institutions?
Currently 0.689% of Blueprint Medicines shares are held by insiders and 111.926% by institutions. How many people work for Blueprint Medicines?
Latest data suggests 580 work at Blueprint Medicines. When does the fiscal year end for Blueprint Medicines?
Blueprint Medicines's fiscal year ends in December. Where is Blueprint Medicines based?
Blueprint Medicines's address is: 45 Sidney Street, Cambridge, MA, United States, 02139 What is Blueprint Medicines's ISIN number?
Blueprint Medicines's international securities identification number is: US09627Y1091 What is Blueprint Medicines's CUSIP number?
Blueprint Medicines's Committee on Uniform Securities Identification Procedures number is: 09627Y109
More guides on Finder
How to buy YanGuFang International Group (YGF) stock when it goes public
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
What are the FAANG stocks and how do you invest in them?
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
How to buy soccer stocks
A simple guide to buying stocks in your favorite European soccer team.
How to buy Juventus stock
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
How to buy AS Roma stock
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
How to buy Borussia Dortmund stock
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
How to buy Lead Real Estate Co. (LRE) stock when it goes public
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
How to buy Third Harmonic Bio (THRD) stock
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
How to buy LINKBANCORP (LNKB) stock
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.
Ask an Expert